Bristol Myers Squibb And Rayzebio Announced Expiration Of Waiting Period Under Hart-scott-rodino Antitrust Improvements Act Of 1976, In Connection With Bristol Myers Squibb's Previously Announced Deal To Acquire Rayzebio For $62.50/Shares On Feb 9